Dose selection in phase I studies: why we should always go for the top

Review

Stefan Sleijfer et al. J Clin Oncol. 2008.

. 2008 Apr 1;26(10):1576-8.

doi: 10.1200/JCO.2007.15.5192. Epub 2008 Mar 10.

No abstract available

Comment in

Dose selection in phase I studies: why we should always go for the most effective.
Haines IE. Haines IE. J Clin Oncol. 2008 Jul 20;26(21):3650-2; author reply 3652-3. doi: 10.1200/JCO.2008.17.6719. J Clin Oncol. 2008. PMID: 18640947 No abstract available.

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. Tabernero J, et al. J Clin Oncol. 2008 Apr 1;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Epub 2008 Mar 10. J Clin Oncol. 2008. PMID: 18332469 Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.
O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. O'Donnell A, et al. J Clin Oncol. 2008 Apr 1;26(10):1588-95. doi: 10.1200/JCO.2007.14.0988. Epub 2008 Mar 10. J Clin Oncol. 2008. PMID: 18332470 Clinical Trial.